Women's Hormone & Menopause Panel

A women's hormone blood panel covering oestrogen, progesterone, FSH, LH and related markers to assess menopausal status, perimenopause and hormonal balance. Includes thyroid function, metabolic markers and a GP consultation to guide HRT or lifestyle decisions.

Elyon Clinic offers a women's hormone and menopause panel for women navigating perimenopause and menopause, experiencing unexplained hormonal symptoms, or seeking a baseline assessment of their reproductive and metabolic hormone status. The clinic takes a practical, patient-centred approach to women's hormonal health, offering clear communication and transparent pricing in contrast to the opaque billing that can characterise specialist-only pathways. The core panel measures oestradiol (E2), follicle-stimulating hormone (FSH) and luteinising hormone (LH) — the key markers for assessing ovarian reserve and menopausal status. Elevated FSH in the context of low oestradiol is a reliable indicator of ovarian insufficiency or menopause. Progesterone is included to assess luteal function in women who are still cycling but experiencing cycle irregularity or premenstrual symptoms. Prolactin is measured because hyperprolactinaemia can cause cycle disruption and is an important differential in women presenting with secondary amenorrhoea. Thyroid function (TSH, free T4) is a standard inclusion because hypothyroidism is common in women, shares many symptoms with menopause — including fatigue, weight changes, mood disturbance and brain fog — and can compound menopausal symptoms if untreated. DHEA-S and testosterone are measured where there is concern about adrenal function or symptoms of androgen excess or deficiency. Metabolic markers including fasting glucose, HbA1c, lipid profile and liver function tests are incorporated because oestrogen deficiency in menopause accelerates cardiovascular risk and bone loss. Understanding the metabolic baseline is important for counselling about hormone replacement therapy (HRT), particularly in women with pre-existing cardiovascular risk factors. Results are reviewed in a GP consultation. For women with confirmed oestrogen deficiency or perimenopausal symptoms, the doctor will discuss HRT options including systemic and topical preparations, discussing risks and benefits in the context of individual health history. The clinic's emphasis on shared decision-making and no-hidden-costs pricing means patients leave with a clear understanding of both the clinical picture and any proposed next steps.